Sees Adjusted EBITDA of $420 million to $425 million; Cash flow from operations of at least $350 million, inclusive of the Amedisys merger termination fee net of merger-related expenses; Additionally, the Company anticipates an effective tax rate of approximately 27% and net interest expense of approximately $52.0 million to $54.0 million.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on OPCH:
- Option Care Health Announces Financial Results for the Third Quarter Ended September 30, 2023
- OPCH Earnings this Week: How Will it Perform?
- Option Care Health price target lowered to $44 from $46 at JPMorgan
- Option Care Health to Announce Third Quarter 2023 Financial Results and Host Conference Call
- Billionaire Stanley Druckenmiller Says Recession Is Still in the Cards, but Stays Heavily Invested in These 2 Stocks
